Advanced Prostate Cancer Consensus Conference (APCCC 2021)
Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study
Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera
ESMO (European Society for Medical Oncology) Congress
NANETS (North American Neuroendocrine Tumor Society) Symposium
WorldMEN (17th International Workshop on Multiple Endocrine Neoplasia and other Rare Endocrine Tumors)
Novartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)
23rd European Congress of Endocrinology (ECE)
Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer
34th Annual Congress of the European Association of Nuclear Medicine (EANM)